UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the
Securities Exchange Act of 1934
(Amendment No. 4)
RAPT
THERAPEUTICS INC
(Name of Issuer)
COMMON
STOCK
(Title of Class of Securities)
75382E109
(CUSIP NUMBER)
December 31, 2022
(Date of Event which Requires Filing of Statement)
Check the appropriate box to designate the
Rule pursuant to which this
Schedule is filed:
[x] Rule 13d - 1(b)
Rule 13d - 1(c)
Rule 13d - 1(d)
1. Name of Reporting Person
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
2. Check the Appropriate Box if a Member of a Group
NOT APPLICABLE
3. SEC Use Only
4. Citizenship or Place of Organization Maryland
Number of
Shares Beneficially Owned by Each Reporting Person With
5. Sole Voting Power* 672,348
6. Shared Voting Power* 0
7. Sole Dispositive Power* 3,364,887
8. Shared Dispositive Power 0
|
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,364,887
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
NOT APPLICABLE
11. Percent of Class Represented by Amount in Row 9 9.9%
12. Type of Reporting Person
IA
*Any shares reported in Items 5 and 6 are also
reported in Item 7.
1. Name of Reporting Person
T. ROWE PRICE NEW HORIZONS FUND, INC. 52-0791372
2. Check the Appropriate Box if a Member of a Group
NOT APPLICABLE
3. SEC Use Only
4. Citizenship or Place of Organization Maryland
Number of Shares Beneficially
Owned by Each Reporting Person With
5. Sole Voting Power* 1,906,994
6. Shared Voting Power* 0
7. Sole Dispositive Power* 0
8. Shared Dispositive Power 0
|
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,906,994
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
NOT APPLICABLE
11. Percent of Class Represented by Amount in Row 9 5.6%
12. Type of Reporting Person
IV
*Any shares reported in Items 5 and 6 are also reported in Item
7.
Item 1(a) Name of Issuer:
RAPT THERAPEUTICS INC
Item 1(b) Address of Issuer's
Principal Executive Offices:
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CALIFORNIA 94080
Item 2(a) Name of Person(s)
Filing:
(1) T. ROWE PRICE ASSOCIATES, INC. (Price
Associates)
(2) T. ROWE PRICE NEW HORIZONS FUND, INC.
X Attached as Exhibit A is a copy of an agreement between the
Persons Filing (as specified hereinabove) that this Schedule 13G is
being filed on behalf of each of them.
Item 2(b) Address of Principal
Business Office:
100 E. Pratt Street, Baltimore, MD
21202
Item 2(c) Citizenship or Place
of Organization:
(1) Maryland
(2) Maryland
Item 2(d) Title of Class of
Securities: COMMON STOCK
Item 2(e) Cusip Number:
75382E109
Item 3: The person filing this
Schedule 13G is an:
X Investment Adviser registered
under Section 203 of the Investment Advisers Act of 1940
X Investment Company registered under Section 8 of the Investment
Company Act of 1940
Item 4: Reference is made to
Items 5-11 on the preceding pages of this Schedule 13G.
Item 5: Ownership of Five
Percent or Less of a Class
Not Applicable
Item 6: Ownership of More than
Five Percent on Behalf of Another Person
(1) Price Associates does not serve as custodian of the assets
of any of its clients; accordingly, in each instance only the
client or the client's custodian or trustee bank has the right to
receive dividends paid with respect to, and proceeds from the sale
of, such securities.
The ultimate power to direct the receipt of dividends paid with
respect to, and the proceeds from the sale of, such securities, is
vested in the individual and institutional clients which Price
Associates serves as investment adviser.
Any and all discretionary authority which has been delegated to
Price Associates may be revoked
in whole or in part at any time.
Except as may be indicated if this is a joint filing with one of
the registered investment companies sponsored by Price Associates
which it also serves as investment adviser ("T. Rowe Price Funds"),
not more than 5% of the class of such securities is owned by any
one client subject to the investment advice of Price
Associates.
(2) With respect to securities owned by any one of the T. Rowe
Price Funds, only the custodian for each of such Funds, has the
right to receive dividends paid with respect to, and proceeds from
the sale of, such securities. No other person is known to have such
right, except that the shareholders of each such Fund participate
proportionately in any dividends and distributions so paid.
Item 7: Identification and
Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company. Not
Applicable
Item 8: Identification and
Classification of Members of the Group
Not Applicable
Item 9: Notice of Dissolution of
Group
Not Applicable
Item 10:
Certification
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above
were acquired in the ordinary course of business and were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect. T.
Rowe Price Associates, Inc. hereby declares and affirms that the
filing of Schedule 13G shall not be construed as an admission that
Price Associates is the beneficial owner of the securities referred
to, which beneficial ownership is expressly denied.
Signature.
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
T. ROWE PRICE ASSOCIATES,
INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
T. ROWE PRICE NEW HORIZONS FUND, INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
12/31/2022
|
EXHIBIT A
AGREEMENT
JOINT FILING OF SCHEDULE 13G
Price Associates, Inc. (an investment adviser registered under
the Investment Advisers Act of 1940), and
T. ROWE PRICE NEW HORIZONS FUND, INC.,
all of which are
Maryland corporations, hereby agree to file jointly the statement
on Schedule 13G to which this Agreement is attached, and any
amendments thereto which may be deemed necessary, pursuant to
Regulation 13D-G under the Securities Exchange Act of 1934.
It is understood and agreed that each of the parties hereto is
responsible for the timely filing of such statement and any
amendments thereto, and for the completeness and accuracy of the
information concerning such party contained therein, but such party
is not responsible for the completeness or accuracy of information
concerning the other party unless such party knows or has reason to
believe that such information is inaccurate.
It is understood and agreed that a copy of this Agreement shall
be attached as an exhibit to the statement on Schedule 13G, and any
amendments hereto, filed on behalf of each of the parties
hereto.
T. ROWE PRICE ASSOCIATES,
INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
T. ROWE PRICE NEW HORIZONS FUND, INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
|
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2023 to Jun 2023
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Jun 2022 to Jun 2023
